



Section: [8. Immunomodulators and antineoplastics](#) > [8.2. Antineoplastics and supportive medicines](#) > [8.2.4. Hormones and antihormones](#)

EMLc

ATC codes: [H02AB04](#)

Indication	Lymphoid leukaemia, not elsewhere classified	ICD11 code: <a href="#">2B33.3</a>
INN	Methylprednisolone	
Medicine type	Chemical agent	
List type	Complementary (EML) (EMLc)	
Formulations	Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc) ; 40 mg per mL in 5 mL multi-dose vial (as sodium succinate) (EMLc) ; 80 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc)	
EML status history	First added in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )	
Sex	All	
Age	Children (1 month - 12 years)	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . <a href="#">↗</a>	

Tags

Cancer

Wikipedia

[Methylprednisolone](#) [↗](#)

DrugBank

[Methylprednisolone](#) [↗](#)

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methylprednisolone injection on the complementary list of the EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.

[Expert Committee report](#) [📎](#)